Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

The José Baselga Lab: Publications

Visit PubMed for a full listing of José Baselga’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 Mar 24;355(6331):1324-30.

Castel, P., Carmona, F.J., Grego-Bessa, J., Berger, M.F., Viale, A., Anderson, K.V., Bague, S., Scaltriti, M., Antonescu, C.R., Baselga, E. and Baselga, J., 2016. Somatic PIK3CA mutations as a driver of sporadic venous malformations. <Science translational medicine, 8(332), pp.332ra42-332ra4 [PMID: 27030594]

Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F.J., Kannan, S., Verma, C.S., Dickler, M., Chandarlapaty, S. and Brogi, E., 2016. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition. Cancer cell, 30(2), pp.229-242.

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J.J., Spratt, D.E., Viola-Villegas, N.T., Castel, P. and Minuesa, G., 2015. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer. Science translational medicine, 7(283), pp.283ra51-283ra51.

Juric D, Castel P, Griffit M, Griffith OL, Won HH, Ellis H, Ebbesen S, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J*, Scaltriti M. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor. Nature. 2015. DOI: 10.1038/nature13948. PMC In-Progress. *Corresponding author.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixido C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL Mediates Resistance to PI3Kalpha Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell. 2015;27(4):533-46. PMCID: PMCPmc4398915.